Table 1 Demographic and disease characteristics before and after IPTW
Characteristics | TH group (n = 384) | THP group (n = 396) | ||||||
|---|---|---|---|---|---|---|---|---|
Low | High | P value | PS weighted P | Low | High | P value | PS weighted P | |
Age, years-no. (%) | ||||||||
< 55 | 167 (87.0) | 153 (79.7) | 0.055 | 0.906 | 111 (56.3) | 93 (46.7) | 0.056 | 0.984 |
≥ 55 | 25 (13.0) | 39 (20.3) | 86 (43.7) | 106 (53.3) | ||||
Disease type at screening-no. (%) | ||||||||
Nonvisceral | 50 (26.0) | 36 (18.8) | 0.087 | 0.934 | 47 (23.9) | 36 (18.1) | 0.159 | 0.992 |
Visceral | 142 (74.0) | 156 (81.2) | 150 (76.1) | 163 (81.9) | ||||
ECOG performance status-no. (%) | ||||||||
0 | 130 (67.7) | 101 (52.6) | 0.003 | 0.853 | 140 (71.1) | 131 (65.8) | 0.262 | 0.991 |
≥ 1 | 62 (32.3) | 91 (47.4) | 57 (28.9) | 68 (34.2) | ||||
Hormone-receptor status-no. (%) | ||||||||
Positive | 95 (49.5) | 90 (46.9) | 0.069 | 0.977 | 99 (50.3) | 109 (54.8) | 0.420 | 0.697 |
Negative | 88 (45.8) | 100 (52.1) | 97 (49.2) | 90 (45.2) | ||||
Unknown | 9 (4.7) | 2 (1.0) | 1 (0.5) | 0 (0) | ||||
Previous neoadjuvant or adjuvant systemic therapy-no. (%) | ||||||||
No | 99 (51.6) | 105 (54.7) | 0.539 | 0.927 | 112 (56.9) | 105 (52.8) | 0.414 | 0.986 |
Yes | 93 (48.4) | 87 (45.3) | 85 (43.1) | 94 (47.2) | ||||